[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 429
1. Miyazawa M, Yasuda M, Fujita M, Hirasawa T, Kajiwara H, Hirabayashi K, Ogane N, Shimizu M, Asanuma H, Murakami M, Takekoshi S, Mikami M, Osamura RY: Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: a quantitative analysis of HIF-1. Arch Gynecol Obstet; 2009 Jun;279(6):789-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: HIF-1 level in the nucleus was analyzed using DNA binding assay, and HIF-1alpha level in the cytoplasm was measured by ELISA for a total of 36 epithelial ovarian tumors as follows: 5 serous adenocarcinomas (SEAs), 7 clear cell adenocarcinomas (CLAs), 7 endometrioid adenocarcinomas (ENAs), 4 mucinous adenocarcinomas (MUAs), 2 mucinous borderline tumors (MBTs), and 11 mucinous adenomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Anoxia / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936945.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 9007-49-2 / DNA
  •  go-up   go-down


2. Catasus L, Gallardo A, Cuatrecasas M, Prat J: PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol; 2008 Feb;21(2):131-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
  • To determine the clinicopathological and molecular implications of these mutations, PIK3CA status was investigated in 109 endometrial (102 endometrioid and 7 mixed) carcinomas and the results were compared with clinicopathological parameters associated with prognosis.
  • Almost all mutated tumors were pure endometrioid adenocarcinomas.
  • Furthermore, whereas 64% of adenocarcinomas with exon 9 mutations had invaded < or =(1/2) of the myometrial thickness (stage IB), 73% of tumors with exon 20 mutations had either deeper myometrial invasion (stage IC) or cervical involvement (stage II) (P=0.045).
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Exons / genetics. Mutation, Missense. Phosphatidylinositol 3-Kinases / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084252.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human
  •  go-up   go-down


3. Ismiil N, Rasty G, Ghorab Z, Nofech-Mozes S, Bernardini M, Ackerman I, Thomas G, Covens A, Khalifa MA: Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion. Ann Diagn Pathol; 2007 Aug;11(4):252-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion.
  • Adenomyosis is commonly seen in association with endometrial adenocarcinoma where it may or may not be involved by malignancy.
  • This study of grade 1 endometrioid adenocarcinoma investigates whether patients with cancer-positive adenomyosis are at a different risk for deep myometrial invasion compared with those with cancer-negative adenomyosis.
  • Ninety-three hysterectomy specimens with FIGO (International Federation of Gynecologists and Obstetricians) grade 1 endometrial endometrioid adenocarcinoma associated with adenomyosis were studied.
  • Adenomyosis was involved by adenocarcinoma in 46 cases, whereas it was carcinoma-negative in 47 cases.
  • Among all cases of FIGO grade 1 endometrial endometrioid adenocarcinoma associated with adenomyosis, the ones that extend in the adenomyosis gain more invasive advantage, probably through increasing the surface area of its interface with the adjacent myometrium.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology. Myometrium / pathology

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630108.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


Advertisement
4. Brüning A, Jückstock J, Blankenstein T, Makovitzky J, Kunze S, Mylonas I: The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas. Histol Histopathol; 2010 11;25(11):1447-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomas.
  • Therefore, the aim of this study was to investigate the expression of this protein in endometrial adenocarcinomas and to analyse potential correlations between this nuclear transcription factor and estrogen receptors in endometrial adenocarcinomas.
  • Additionally, we evaluated whether MTA3 might be a prognostic parameter in endometrioid adenocarcinomas.
  • Endometrioid adenocarcinomas were obtained from 200 patients and immunohistochemically analysed for MTA3 and estrogen receptor alpha and beta (ER-alpha and ER-beta) expression.
  • Overall, endometrioid adeno-carcinomas of histological differentiation grade 3 demonstrated a significantly lower expression of MTA3 compared to carcinomas of histological grade 1 and 2 (p<0.05).
  • MTA3 expression is reduced in endometrioid adenocarcinomas of poor differentiation, though without any correlation to ER-alpha and ER-beta expression.
  • Overall, MTA3 did not constitute an independent prognostic factor in this study, suggesting that MTA3 is not a useful marker to assess and identify high-risk patients with endometrial adenocarcinomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20865667.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MTA3 protein, human; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen
  •  go-up   go-down


5. Ota K, Ito K, Akahira J, Sato N, Onogawa T, Moriya T, Unno M, Abe T, Niikura H, Takano T, Yaegashi N: Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer. Int J Gynecol Pathol; 2007 Jul;26(3):334-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median value of relative SLC22A16 gene expression in cell lines derived from clear-cell adenocarcinoma was significantly higher than that in cell lines from other histologies (P < 0.001).
  • Expression of SLC22A16 protein was also detected in cell lines derived from clear-cell adenocarcinoma.
  • In ovarian cancer tissues, SLC22A16 immunoreactivity was detected in 2 (5%) of 38 serous adenocarcinoma, 1 (6.7%) of 15 endometrioid adenocarcinoma, 0 (0%) of 14 mucinous adenocarcinoma, and 12 (46.2%) of 26 clear-cell adenocarcinoma (P < 0.0001, clear-cell vs other histologies).
  • In conclusion, SLC22A16 was abundantly expressed in clear-cell adenocarcinoma.
  • Our results suggest that adriamycin-related chemicals that are taken up via SLC22A16 may have the potential to be effective against clear-cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Antibiotics, Antineoplastic / pharmacokinetics. Doxorubicin / pharmacokinetics. Organic Cation Transport Proteins / biosynthesis. Ovarian Neoplasms / metabolism


6. McKenney JK, Longacre TA: Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics. Adv Anat Pathol; 2009 Jan;16(1):1-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics.
  • The distinction between endometrial hyperplasia and well-differentiated adenocarcinoma of the endometrium continues to be a difficult differential diagnosis in surgical pathology.
  • Evidence-based diagnostic criteria for well-differentiated endometrial adenocarcinoma focus on histologic features that predict myoinvasion in the hysterectomy specimen.
  • Application of these 2 criteria in problematic endometrial proliferations allows stratification of patients into 3 risk categories: very low risk (< 0.05% risk of myoinvasion at hysterectomy)=complex atypical hyperplasia; intermediate risk (5.5% risk of myoinvasion at hysterectomy)=complex atypical hyperplasia, cannot exclude well-differentiated adenocarcinoma (borderline); and high risk (20% risk of myoinvasion at hysterectomy)=well-differentiated adenocarcinoma.
  • In order to optimize the use of these diagnostic criteria, a variety of gland forming lesions that may mimic well-differentiated endometrioid adenocarcinoma must first be excluded.
  • In addition, unusual morphologic patterns of low-grade endometrioid adenocarcinoma should be recognized, as they may cause confusion with other, higher grade (and therefore, more clinically aggressive) endometrial processes.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Endometrium / pathology. Uterine Diseases / pathology

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098463.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 58
  •  go-up   go-down


7. Hanley KZ, Dustin SM, Stoler MH, Atkins KA: The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma. Int J Gynecol Pathol; 2010 Sep;29(5):445-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of tumor involved adenomyosis in otherwise low-stage endometrioid adenocarcinoma.
  • Depth of myometrial invasion by endometrioid adenocarcinoma (EMAC) is one of the most important predictive factors of disease recurrence.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology

  • Genetic Alliance. consumer health - Adenomyosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736770.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Stolnicu S, Preda O, Dohan M, Puscasiu L, García-Galvis OF, Nogales FF: Pseudoglandular hepatoid differentiation in endometrioid carcinoma of the ovary simulates oxyphilic cell change. Int J Gynecol Pathol; 2008 Oct;27(4):521-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoglandular hepatoid differentiation in endometrioid carcinoma of the ovary simulates oxyphilic cell change.
  • A 42-year-old patient had a stage III ovarian endometrioid adenocarcinoma with areas of hepatoid carcinoma (HC) of clear cell and eosinophilic pseudoglandular type that was difficult to differentiate from endometrioid carcinoma of oxyphilic type and sex cord-stromal tumor.
  • Immunohistochemically, endometrioid adenocarcinoma was positive for CA125, estrogen and progesterone receptors, CAM5.2, cytokeratin (CK) 7 and 19, and vimentin.
  • HC areas were positive for hep par1, polyclonal carcinoembryonic antigens, CD10, alpha-fetoprotein, epithelial membrane antigens, and antimitochondrial antibodies and shared with endometrioid carcinoma focal CK7, and constant positive CK19, CAM5.2, and progesterone receptors.
  • The partial preservation of an endometrioid immunophenotype in HC (positive CK7 and 19 and progesterone receptors) would support an origin from endometrioid carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753970.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Lin CK, Chao TK, Yu CP, Yu MH, Jin JS: The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS; 2009 Mar;117(3):162-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six biomarkers were investigated immunohistochemically using tissue microarrays of 185 specimens including 79 serous cystadenocarcinomas, 47 mucinous cystadenocarcinomas, 45 endometrioid adenocarcinomas, and 14 clear cell carcinomas.
  • In addition, higher immunostaining scores for fascin-1, cortactin, and survivin correlated with poorer tumor differentiation in serous, mucinous, and endometrioid adenocarcinomas.
  • Thus, the expression of fascin-1, cortactin, and survivin may be helpful in evaluating the aggressiveness of ovarian mucinous, serous, and clear cell adenocarcinoma.
  • Additionally, the expression of fascin-1 may be an independent prognostic risk factor in mucinous cystadenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19245589.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cortactin; 0 / FSCN1 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microfilament Proteins; 0 / Microtubule-Associated Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


10. Hwang JH, Lee JK, Lee NW, Lee KW: Primary small cell carcinoma of the endometrium: report of a case with immunochemical studies. J Reprod Med; 2010 Jan-Feb;55(1-2):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of an endometrial tumor that was a combination of an SCC and endometrioid adenocarcinoma with squamous components and that penetrated half of the thickness of the uterine wall.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337215.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Synaptophysin
  •  go-up   go-down


11. Silverberg SG: The endometrium. Arch Pathol Lab Med; 2007 Mar;131(3):372-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To emphasize practical aspects of endometrial specimen handling and reporting, with selected comments on common diagnostic pitfalls, including (1) the diagnosis of endometrial intraepithelial carcinoma in atrophic endometrial biopsy specimens, (2) evaluation of adequacy of endometrial sampling specimens, (3) problems in diagnosing and measuring the depth of myometrial invasion in endometrial carcinoma, (4) the question of metastasis versus independent primaries in concurrent carcinomas of endometrium and one or both ovaries, (5) the problematic differential diagnoses between type 1 (primarily endometrioid) and type 2 (primarily serous) adenocarcinomas, and (6) atypical hyperplasia and proposed classification systems for its replacement.
  • [MeSH-minor] Adenocarcinoma / pathology. Biopsy. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Hysterectomy. Myometrium / pathology. Pathology, Clinical / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17516740.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


12. Higashiguchi A, Yamada T, Susumu N, Mori T, Suzuki A, Aoki D, Sakamoto M: Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis. Cancer Sci; 2007 Mar;98(3):387-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis.
  • Ascitic cytological diagnosis is critical, but ovarian adenocarcinoma cells and reactive mesothelial cells can be difficult to distinguish because they usually have atypical cell nuclei and increased nuclear/cytoplasmic ratios.
  • Previous studies using DNA microarrays have demonstrated that hepatocyte nuclear factor-1beta (HNF-1beta) is expressed specifically in clear cell adenocarcinoma (CCC).
  • We first confirmed that HNF-1beta expression levels were significantly higher in CCC than in non-CCC (i.e. serous adenocarcinoma, mucinous adenocarcinoma and endometrioid adenocarcinoma) in 55 surgical specimens at both the mRNA (P < 0.05) and protein (P < 0.05) levels by real-time polymerase chain reaction and immunohistochemistry, respectively.
  • Immunocytochemistry of 60 cytological specimens showed significant positivity in CCC cases whereas all non-CCC cells, except for three endometrioid adenocaricnoma cases, and mesothelial cells in the background stained negatively for anti-HNF-1beta antibody (P < 0.05).
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / metabolism. Hepatocyte Nuclear Factor 1-beta / metabolism. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270029.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


13. Mulvany NJ, Mitchell G, Allen DG: Adenocarcinoma cells in Pap smears. Pathology; 2009;41(5):411-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma cells in Pap smears.
  • Adenocarcinomas of the cervix, endometrium, fallopian tube and ovary may present with malignant cells in a Pap smear.
  • Consideration of all of these points in conjunction with an appreciation of the classical cytomorphology of endometrioid, serous and clear cell carcinomas should allow a correct diagnosis of extrauterine adenocarcinoma with a high degree of probability.
  • [MeSH-major] Adenocarcinoma / diagnosis. Genital Neoplasms, Female / diagnosis. Papanicolaou Test. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900079.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 106
  •  go-up   go-down


14. Ferchichi L, Rammeh-Rommani S, Ben Hammouda S, Sfar R, Farah F, Ben Jilani S, Zermani R: [Endometrioid adenocarcinoma of the uterine cervix associated with mucinous ovarian cystadenocarcinoma]. Gynecol Obstet Fertil; 2006 May;34(5):410-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrioid adenocarcinoma of the uterine cervix associated with mucinous ovarian cystadenocarcinoma].
  • [Transliterated title] Association d'un adénocarcinome du col de type endométrioïde à un cystadénocarcinome mucineux de l'ovaire.
  • The authors report the case of a 40-year-old woman, who was operated for an ovarian mucinous cystadenocarcinoma.
  • The pathologic findings of the hysterectomy specimen with bilateral salpingoophorectomy showed an ovarian mucinous cystadenocarcinoma associated with an endometrioid adenocarcinoma of the uterine cervix.
  • The mucinous cystadenocarcinoma represents the third most common type of ovarian carcinoma.
  • In the literature, this tumor had been found in association with endocervical adenocarcinoma or with minimal deviation adenocarcinoma (adenoma malignum) of the uterine cervix.
  • However, its association with an endometrioid adenocarcinoma, to our knowledge, has not been reported.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology


15. Gomes CP, Andrade LA: PTEN and p53 expression in primary ovarian carcinomas: immunohistochemical study and discussion of pathogenetic mechanisms. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have studied their immunohistochemical expression in 70 cases of primary ovarian carcinomas (26 serous, 27 endometrioid, and 17 mucinous) and compared the results with morphologic parameters (histologic grade, subtype) and clinical data (age, stage, tumor size).
  • The loss of expression of PTEN was significantly more frequent in grade 1 endometrioid adenocarcinomas.
  • These markers did not show association with volume or stage of the tumor. p53 is associated with serous carcinoma, loss of differentiation, and older patients, whereas PTEN inactivation is an early event in carcinogenesis of the endometrioid subtype, as observed in type I endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Ovarian Neoplasms / metabolism. PTEN Phosphohydrolase / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515600.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


16. Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus RR, Richer JK: ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol; 2008 Jul;21(7):912-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we quantify ZEB1 protein expression in endometrial samples from 88 patients and confirm that it is expressed at significantly higher levels in the tumor-associated stroma of low-grade endometrioid adenocarcinomas (type I endometrial cancers) compared to hyperplastic or normal endometrium.
  • In addition, as we previously reported, ZEB1 is aberrantly expressed in the epithelial-derived tumor cells of highly aggressive endometrial cancers, such as FIGO grade 3 endometrioid adenocarcinomas, uterine serous carcinomas, and malignant mixed Müllerian tumors (classified as type II endometrial cancers).
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Homeodomain Proteins / metabolism. Transcription Factors / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487993.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA098258; United States / NCI NIH HHS / CA / CA26869; United States / NCI NIH HHS / CA / P30-CA46934
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / ZEB1 protein, human
  •  go-up   go-down


17. Wani Y: Interpretation of diffuse Cdx2 expression in endometrioid adenocarcinoma in the absence of morules. Histopathology; 2009 Mar;54(4):495-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interpretation of diffuse Cdx2 expression in endometrioid adenocarcinoma in the absence of morules.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Homeodomain Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Histopathology. 2008 Aug;53(2):156-65 [18752499.001]
  • (PMID = 19309406.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / beta Catenin
  •  go-up   go-down


18. Temkin SM, Pezzullo JC, Hellmann M, Lee YC, Abulafia O: Is body mass index an independent risk factor of survival among patients with endometrial cancer? Am J Clin Oncol; 2007 Feb;30(1):8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate whether body mass index (BMI) is an independent risk factor for survival in patients with endometrial adenocarcinoma.
  • The first included patients with low-grade endometrioid adenocarcinoma (FIGO grades 1 and 2); the second included grade 3 endometrioid adenocarcinoma; and the third contained papillary serous and clear cell carcinomas.
  • There were 312 patients (70%) treated for low-grade endometrial adenocarcinoma; 64 patients (14%) for grade 3 endometrioid adenocarcinoma; and 71 patients (16%) for papillary serous and clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / physiopathology. Body Mass Index. Endometrial Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278888.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Saji H, Kurose K, Sugiura K, Miyagi E, Onose R, Kato H, Nakayama H: Endometrial aspiration cytology for diagnosis of peritoneal lesions in extrauterine malignancies. Acta Cytol; 2007 Jul-Aug;51(4):533-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic positive rates were: serous, 28.7%; mucinous, 11.4%; clear cell, 23.1%; endometrioid and unclassifiable adenocarcinomas, 28.0%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718117.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. McCluggage WG: My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol; 2008 Feb;61(2):152-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are several areas where there are particular difficulties; these include the distinction between high-grade serous and endometrioid adenocarcinomas and the distinction between a true clear cell carcinoma and clear cell areas within other adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / classification. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / classification. Carcinoma, Endometrioid / pathology. Carcinoma, Transitional Cell / classification. Carcinoma, Transitional Cell / pathology. Cystadenocarcinoma, Serous / classification. Cystadenocarcinoma, Serous / pathology. Female. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704261.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 89
  •  go-up   go-down


21. Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, Wright JD: Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol; 2008 Jul;112(1):64-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
  • OBJECTIVE: To compare the clinical behavior and outcome of uterine carcinosarcomas and grade 3 endometrioid carcinomas.
  • METHODS: Data on patients with grade 3 endometrioid adenocarcinomas and uterine carcinosarcomas, from 1988 to 2004, was obtained from the Surveillance, Epidemiology, and End Results database.
  • RESULTS: The cohort included 8,986 women with 5,024 (56%) grade 3 endometrioid carcinomas and 3,962 (44%) uterine carcinosarcomas.
  • Cancer-specific mortality was 45% lower in women with grade 3 endometrioid carcinomas (hazard ratio 0.55; 95% confidence interval [CI] 0.5-0.6).
  • Survival for stage IC was 38% (95% CI 33-45%) for uterine carcinosarcoma compared with 68% (95% CI 63-73%) for grade 3 endometrioid carcinoma.
  • For stage III, survival was 22% (95% CI 19-26%) for uterine carcinosarcoma compared with 45% (95% CI 41-49%) for grade 3 endometrioid carcinoma.
  • CONCLUSION: Carcinosarcomas present at more advanced stage and have worse survival than grade 3 endometrioid carcinomas.
  • [MeSH-major] Carcinoma, Endometrioid / mortality. Carcinosarcoma / mortality. Endometrial Neoplasms / mortality. SEER Program. Uterine Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591309.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Ragni N, Ferrero S, Prefumo F, Muschiato B, Gorlero F, Gualco M, Fulcheri E: The association between p53 expression, stage and histological features in endometrial cancer. Eur J Obstet Gynecol Reprod Biol; 2005 Nov 1;123(1):111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Uterine papillary serous adenocarcinomas showed significantly higher p53 overexpression than uterine endometrioid adenocarcinomas (100.0% versus 61.0%, p<0.005).
  • p53 overexpression was significantly higher in the secretory variant (85.7%) than in the typical endometrioid carcinoma (60.0%) (p<0.05).

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894417.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Salerno MG, Masciullo V, Naldini A, Zannoni GF, Vellone V, Scambia G: Endometrioid adenocarcinoma with squamous differentiation arising from ureteral endometriosis in a patient with no history of gonadal endometriosis. Gynecol Oncol; 2005 Dec;99(3):749-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma with squamous differentiation arising from ureteral endometriosis in a patient with no history of gonadal endometriosis.
  • CASE: An endometrioid carcinoma with squamous differentiation arising from periureteral endometriosis presented as a pelvic mass encasing the right ureter.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Squamous Cell / pathology. Endometriosis / pathology. Ureteral Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226301.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, del Carmen MG: Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol; 2009 Jun;113(3):316-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
  • OBJECTIVES: Endometrioid adenocarcinoma of the endometrium (EEC) is the most common histologic type of endometrial cancer, with stage being the most critical prognostic factor.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Staging

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345400.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control; 2009 Jan;16(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes.
  • BACKGROUND: Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens.
  • METHODS: The pathology and treatment of selected non-endometrioid endometrial adenocarcinomas of the uterus are reviewed and summarized.
  • RESULTS: The most common non-endometrioid histology is papillary serous (10%), followed by clear cell (2% to 4%), mucinous (0.6% to 5%), and squamous cell (0.1% to 0.5%).
  • Some non-endometrioid endometrial carcinomas behave more aggressively than the endometrioid cancers such that even women with clinical stage I disease often have extrauterine metastasis at the time of surgical evaluation.
  • Therefore, when technically and medically feasible, comprehensive surgical staging is helpful for women with non-endometrioid endometrial cancer histology.
  • The remaining cell types should be treated similar to endometrioid or other low-grade histologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078929.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


26. Huang SY, Jung SM, Ng KK, Chang YC, Lai CH: Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol; 2005 May;97(2):652-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment.
  • CASE: We present a 36-year-old nulliparous woman, initially diagnosed as clinical stage IA, grade 1 endometrial adenocarcinoma, receiving 6-month conservative treatment with remission achieved at 4 months from diagnosis.
  • The final pathology revealed well-differentiated endometrioid adenocarcinoma with inner one-third myometrial invasion and right ovarian metastasis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Megestrol Acetate / therapeutic use. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863173.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


27. Prat J: Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol; 2005 Feb;18 Suppl 2:S99-111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic colon cancer is frequent and often simulates ovarian endometrioid adenocarcinoma.
  • Occasionally, endometrioid carcinomas may exhibit a microglandular pattern simulating sex cord-stromal tumors.
  • However, typical endometrioid glands, squamous differentiation, or an adenofibroma component are each present in 75% of these tumors whereas immunostains for calretinin and alpha-inhibin are negative.
  • Endometrioid carcinoma of the ovary is associated in 15-20% of the cases with carcinoma of the endometrium.
  • Krukenberg tumors are metastatic adenocarcinomas traditionally perceived as composed of mucin-filled signet-ring cells associated with a striking proliferation of the ovarian stroma but many variations on this pattern occur.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492758.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 0 / beta Catenin; 68238-35-7 / Keratins; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 63
  •  go-up   go-down


28. Geisler JP, Buller E, Manahan KJ: Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary. Eur J Gynaecol Oncol; 2008;29(2):126-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary.
  • OBJECTIVE: The purpose of this study was to analyze estrogen receptor alpha and beta (ERalpha, ERbeta) expression in a stage and grade matched cohort of patients with serous and endometrioid adenocarcinoma of the ovary.
  • METHODS: Forty-two patients from 1991 to the present were found to have the diagnosis of endometrioid adenocarcinoma of the ovary and have tissue available for analysis.
  • These were stage and grade matched with ten patients having serous adenocarcinoma of the ovary during the same time period.
  • RESULTS: ERalpha expression was present in ten of ten endometrioid adenocarcinomas but in only five of ten serous carcinomas (chi2, p = 0.01).
  • ERbeta expression was present in six of ten endometrioid adenocarcinomas and in four of ten serous caricinomas (chi2, p = 0.65).
  • CONCLUSIONS: ERalpha expression, but not ERbeta expression, is significantly more common in endometrioid than serous adenocarcinomas of the ovary when controlled for stage and grade.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Estrogen Receptor alpha / genetics. Estrogen Receptor beta / genetics. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459544.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA 79445-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / RNA, Messenger
  •  go-up   go-down


29. Behtash N, Hashemi R, Karimi Zarchi M: Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review. Asian Pac J Cancer Prev; 2009 Jan-Mar;10(1):163-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two cancers were malignant mixed Mullerian tumors of the uterus (MMMT), 2 were endometrioid adenocarcinomas, and one was a papillary clear cell carcinoma.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469647.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


30. Skhiri A, Fkih C, Ben Zineb N: [Endometrioid adenocarcinoma found in the ovary and endometrium: pathologic and therapeutic particularities]. Tunis Med; 2008 Jan;86(1):84-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrioid adenocarcinoma found in the ovary and endometrium: pathologic and therapeutic particularities].
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475734.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Tunisia
  •  go-up   go-down


31. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR: Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol; 2008 Dec 20;26(36):5965-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The clinical records and pathology reports from women who underwent hysterectomy at our institution for endometrial or endocervical adenocarcinoma over an 11-year interval were reviewed.
  • Preoperative diagnosis of the LUS tumors more frequently included the possibility of endocervical adenocarcinoma.
  • Seventy-three percent of the LUS tumors had an immunohistochemical expression pattern typical of conventional endometrioid adenocarcinoma.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1984 Jun;63(6):825-32 [6728365.001]
  • [Cites] Obstet Gynecol. 1970 Jul;36(1):76-81 [4192878.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(1):26-35 [2707951.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):172-7 [8617459.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):38-44 [8986531.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Diagn Cytopathol. 1999 Aug;21(2):117-21 [10425049.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4609-16 [15837969.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):87-94 [16323174.001]
  • [Cites] Can Assoc Radiol J. 2006 Feb;57(1):43-8 [16719212.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7810-7 [16885385.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2006 Dec;20(6):985-1000 [16895764.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):55-8 [17157904.001]
  • [Cites] N Engl J Med. 2007 Apr 26;356(17):1760-9 [17460231.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5158-64 [17925543.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):513-7 [11733964.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2578-84 [11745192.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):998-1006 [12170086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5908-13 [12732731.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4364-70 [14645426.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):160-7 [15043304.001]
  • [Cites] Dis Colon Rectum. 1988 Jun;31(6):439-44 [3378468.001]
  • (PMID = 19001318.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5T32 CA101642 02; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2645115
  •  go-up   go-down


32. Zhu Y, Sundfeldt K: Tight junction formation in epithelial ovarian adenocarcinoma. Acta Obstet Gynecol Scand; 2007;86(8):1011-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tight junction formation in epithelial ovarian adenocarcinoma.
  • RESULTS: We found expression for all cell-junction proteins with a typical honeycomb-staining pattern in the serous adenocarcinomas indicating proper junction formation.
  • Clear-cell and endometrioid adenocarcinomas showed a different expression pattern.
  • By measuring TER, including Ca(2+) switch experiments, functional TJs were shown to build up only in serous adenocarcinomas.
  • CONCLUSION: Serous adenocarcinomas formed functional TJs in vitro.
  • [MeSH-major] Adenocarcinoma / physiopathology. Ovarian Neoplasms / physiopathology. Tight Junctions / physiology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / physiopathology. Cadherins / metabolism. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / physiopathology. Cell Line, Tumor. Claudin-3. Claudin-4. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / physiopathology. Female. Humans. Membrane Proteins / metabolism. Phosphoproteins / metabolism. Zonula Occludens-1 Protein

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653889.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / Cadherins; 0 / Claudin-3; 0 / Claudin-4; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein
  •  go-up   go-down


33. Oztürk HB, Vural B, Calışkan E, Solakoğlu S: Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines. J Turk Ger Gynecol Assoc; 2010;11(3):131-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.
  • OBJECTIVE: The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines.
  • MATERIAL AND METHOD: Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24591918.001).
  • [ISSN] 1309-0399
  • [Journal-full-title] Journal of the Turkish German Gynecological Association
  • [ISO-abbreviation] J Turk Ger Gynecol Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC3939219
  • [Keywords] NOTNLM ; Endometrial cancer / apoptosis / cell proliferation / gonadotropin-releasing hormone analogues / octreotide
  •  go-up   go-down


34. Arafa M, Kridelka F, Mathias V, Vanbellinghen JF, Renard I, Foidart JM, Boniver J, Delvenne P: High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology; 2008 Nov;53(5):525-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma.
  • AIMS: To identify a DNA methylation signature of endometrioid carcinoma of the endometrium (EEC) in the early stages of endometrial carcinogenesis.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometrial Neoplasms / genetics. Endometrium / metabolism. Promoter Regions, Genetic / genetics. Receptors, Retinoic Acid / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783461.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RARB2 protein, human; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


35. Ozbudak IH, Karaveli S, Simsek T, Erdogan G, Pestereli E: Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol Oncol; 2008 Mar;108(3):603-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas.
  • METHODS: Expression of HIF-1alpha VEGF, and GLUT-1 were analyzed by immunohistochemistry and microvessel density (MVD) was determined by CD 34 immunostaining in 100 endometrioid type endometrial adenocarcinoma, FIGO Stages I-IV.
  • CONCLUSION: HIF-1alpha was increasingly expressed from early stages through advance stages of endometrioid adenocarcinoma, paralleled by activation of its downstream genes such as GLUT-1, VEGF and increased angiogenesis.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / physiopathology. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18191183.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


36. Akcaer M, Milman T, Finger PT: Imaging of endometrioid adenocarcinoma of the uterus metastatic to the ciliary body. Ophthalmic Surg Lasers Imaging; 2008 May-Jun;39(3):246-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of endometrioid adenocarcinoma of the uterus metastatic to the ciliary body.
  • A 60-year-old woman with endometrioid adenocarcinoma (stage FIGO II) presented with left eye pain.
  • A Finger iridectomy technique ciliary body tumor biopsy revealed metastatic endometrioid adenocarcinoma.
  • This is the first reported case of endometrioid adenocarcinoma of the uterus metastatic to the uveal tract.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / secondary. Ciliary Body. Endometrial Neoplasms / pathology. Uveal Neoplasms / diagnosis. Uveal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556953.001).
  • [ISSN] 1542-8877
  • [Journal-full-title] Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
  • [ISO-abbreviation] Ophthalmic Surg Lasers Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Okamoto S, Ito K, Sasano H, Moriya T, Niikura H, Terada Y, Sato S, Okamura K, Yaegashi N: Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells. Tohoku J Exp Med; 2005 May;206(1):31-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various types of ovarian carcinoma (serous, n = 22; mucinous, n = 10; endometrioid, n = 7; clear cell, n = 10) and benign mesothelial tissues (n = 15) were studied by immunohistochemistry.
  • We then studied effective panels of antibodies by immunohistochemistry in 43 cytologic specimens of ascites or peritoneal lavage fluid consisting of 20 reactive mesothelium and 23 adenocarcinomas of the ovary.
  • In conclusion, the combined immunostaining of cytologic specimens for Ber-EP4 and the anti-calretinin antibody is helpful for the differential diagnosis between mesothelial cells and not only serous type, but also mucinous, endometrioid and clear cell types of ovarian cancer cells.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802873.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / human epithelial antigen-125
  •  go-up   go-down


38. Groisman GM, Bernheim J, Halpern M, Brazowsky E, Meir A: Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum. Arch Pathol Lab Med; 2005 Jul;129(7):920-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
  • CONTEXT: Secondary adenocarcinomas of the large bowel can closely mimic primary tumors.
  • The differentiation of secondary from primary adenocarcinomas of the colorectum, however, is important because their clinical management and prognosis are different.
  • Immunostaining with the nuclear transcription factor Cdx2, expressed in normal intestinal epithelia and colorectal adenocarcinomas, could be of potential diagnostic use.
  • OBJECTIVE: To investigate the diagnostic value of Cdx2 immunoexpression in distinguishing primary from common forms of secondary colorectal adenocarcinomas.
  • DESIGN: Cdx2 immunoexpression was analyzed in 20 primary colorectal adenocarcinomas and in 34 secondary colorectal adenocarcinomas and their corresponding primary tumors.
  • All secondary tumors were diagnosed through endoscopic biopsies and included 8 cases of ovarian (4 serous, 2 mucinous, and 2 endometrioid), 6 of mammary (4 lobular and 2 ductal), 4 of gastric (2 intestinal and 2 diffuse), 4 of pulmonary, 4 of pancreatic (ductal), 3 of prostatic, 3 of colorectal, and 2 of endometrial origin.
  • RESULTS: Cdx2 was expressed in normal colorectal epithelium, in primary colorectal adenocarcinomas (20/20 cases), in secondary adenocarcinomas of colorectal (3/3) and gastric (3/4) origin, and in metastatic ovarian mucinous adenocarcinomas (2/2).
  • In contrast, no Cdx2 immunoreactivity was observed in secondary colorectal tumors of ovarian (serous and endometrioid), mammary, pancreatic, pulmonary, prostatic, and endometrial origin.
  • CONCLUSION: Cdx2 immunostaining may be useful in discriminating primary colorectal carcinomas from frequent types of secondary colorectal adenocarcinomas of nongastrointestinal origin.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Colorectal Neoplasms / secondary. Gene Expression Regulation, Neoplastic / genetics. Homeodomain Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15974817.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


39. Abbott KL, Lim JM, Wells L, Benigno BB, McDonald JF, Pierce M: Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics; 2010 Feb;10(3):470-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis.
  • Our study using glycotranscriptome comparative analysis of endometrioid ovarian cancer tissue and normal ovarian tissue led to the identification of distinct differences in the transcripts of a restricted set of glycosyltransferases involved in N-linked glycosylation.
  • The glycoproteins that were verified were then analyzed further using existing microarray data obtained from benign ovarian adenomas, borderline ovarian adenocarcinomas, and malignant ovarian adenocarcinomas.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 May;156(5):1549-56 [10793066.001]
  • [Cites] Environ Health Perspect. 2009 Jul;117(7):1116-23 [19654922.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):3898-906 [11034397.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):298-307 [11058770.001]
  • [Cites] Annu Rev Physiol. 2001;63:521-54 [11181966.001]
  • [Cites] J Immunol. 2001 May 1;166(9):5792-800 [11313423.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17507-14 [11278670.001]
  • [Cites] Immunol Rev. 2001 Apr;180:5-15 [11414363.001]
  • [Cites] Mol Immunol. 2001 Aug;38(2-3):175-87 [11532279.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4141-5 [11591733.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2560-7 [11859152.001]
  • [Cites] Inhal Toxicol. 2002 May;14(5):459-86 [12028803.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):42821-9 [12215441.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 15;31(20):e122 [14530455.001]
  • [Cites] Inhal Toxicol. 2003 Nov;15(13):1309-25 [14569495.001]
  • [Cites] J Allergy Clin Immunol. 2003 Nov;112(5):905-14 [14610479.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50781-90 [14522998.001]
  • [Cites] Clin Immunol. 2003 Dec;109(3):250-65 [14697739.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):119-25 [14726165.001]
  • [Cites] Science. 2004 Jun 11;304(5677):1678-82 [15192232.001]
  • [Cites] Physiol Genomics. 2004 Aug 11;18(3):261-72 [15173550.001]
  • [Cites] J Proteome Res. 2009 Apr;8(4):1631-8 [19714806.001]
  • [Cites] J Immunol. 2000 Jul 1;165(1):108-13 [10861042.001]
  • [Cites] Ann Surg. 1978 Dec;188(6):809-16 [736659.001]
  • [Cites] FEBS Lett. 1992 Dec 21;314(3):386-8 [1281792.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4807-14 [8648128.001]
  • [Cites] J Immunol. 1997 Mar 1;158(5):2406-13 [9036991.001]
  • [Cites] J Exp Med. 1998 May 4;187(9):1537-42 [9565645.001]
  • [Cites] Genomics. 1998 Dec 1;54(2):316-22 [9828134.001]
  • [Cites] Methods Mol Biol. 1999;112:99-103 [10027233.001]
  • [Cites] J Allergy Clin Immunol. 2004 Nov;114(5):1116-23 [15536419.001]
  • [Cites] Electrophoresis. 2005 Jan;26(1):280-92 [15624150.001]
  • [Cites] Science. 2005 May 6;308(5723):804-6 [15879201.001]
  • [Cites] Electrophoresis. 2005 Jun;26(11):2092-108 [15880549.001]
  • [Cites] Immunol Rev. 2005 Aug;206:32-63 [16048541.001]
  • [Cites] Immunol Rev. 2005 Aug;206:83-99 [16048543.001]
  • [Cites] J Allergy Clin Immunol. 2006 Aug;118(2):455-65 [16890772.001]
  • [Cites] Clin Immunol. 2006 Nov;121(2):227-35 [16979384.001]
  • [Cites] J Radiat Res. 2007 Jan;48(1):39-44 [17229997.001]
  • [Cites] Inhal Toxicol. 2007;19 Suppl 1:117-26 [17886059.001]
  • [Cites] Proteomics. 2007 Nov;7(21):3906-18 [17922515.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Dec;37(6):706-19 [17630318.001]
  • [Cites] Arch Med Res. 2008 Aug;39(6):560-6 [18662586.001]
  • [Cites] J Hum Genet. 2008;53(8):728-38 [18566738.001]
  • [Cites] Clin Exp Allergy. 2008 Dec;38(12):1901-10 [19037965.001]
  • [Cites] Clin Immunol. 2009 Feb;130(2):186-98 [18955015.001]
  • [Cites] Yonsei Med J. 2009 Feb 28;50(1):22-30 [19259344.001]
  • [Cites] Annu Rev Physiol. 2009;71:489-507 [19575684.001]
  • [Cites] Hum Gene Ther. 2009 Dec;20(12):1597-606 [19548841.001]
  • (PMID = 19953551.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41RR018502; United States / NCI NIH HHS / CA / R01 CA064462; United States / NCRR NIH HHS / RR / P41 RR018502; United States / NCI NIH HHS / CA / U01 CA128454; United States / NCI NIH HHS / CA / UO1CA128454; United States / NCI NIH HHS / CA / R01CA064462
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Proteome
  • [Other-IDs] NLM/ NIHMS793820; NLM/ PMC4932840
  •  go-up   go-down


40. Kozawa E, Matsuo Y, Hasegawa K, Fujiwara K, Sakurai T, Kimura F: Spontaneously ruptured endometrioma associated with endometrioid adenocarcinoma: MR findings. Magn Reson Med Sci; 2010;9(4):233-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneously ruptured endometrioma associated with endometrioid adenocarcinoma: MR findings.
  • Histologic examination following adnexectomy revealed a ruptured endometrioma associated with endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187693.001).
  • [ISSN] 1880-2206
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


42. Pappa KI, Choleza M, Markaki S, Giannikaki E, Kyroudi A, Vlachos G, Voulgaris Z, Anagnou NP: Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol; 2006 Mar;100(3):596-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the mutations occurred in surgical stage I and in the endometrioid adenocarcinoma subtype.


43. Nomura S, Suganuma T, Suzuki T, Ito T, Kajiyama H, Okada M, Shibata K, Ino K, Kikkawa F, Mizutani S: Endometrioid adenocarcinoma arising from endometriosis during 2 years of estrogen replacement therapy after total hysterectomy and bilateral salpingo-oophorectomy. Acta Obstet Gynecol Scand; 2006;85(8):1019-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma arising from endometriosis during 2 years of estrogen replacement therapy after total hysterectomy and bilateral salpingo-oophorectomy.
  • [MeSH-major] Carcinoma, Endometrioid / etiology. Endometrial Neoplasms / etiology. Endometriosis / therapy. Estrogen Replacement Therapy / adverse effects. Uterine Diseases / therapy

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16862489.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


44. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • We report on a very rare case of peritoneal clear cell adenocarcinomas.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


45. Kobayashi S, Sasaki M, Goto T, Asakage N, Sekine M, Suzuki T, Tsukada K, Yamasaki S, Ukawa S: Endometrioid adenocarcinoma arising from endometriosis of the rectosigmoid. Dig Endosc; 2010 Jan;22(1):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma arising from endometriosis of the rectosigmoid.
  • A case of endometrioid adenocarcinoma supposedly arising from endometriosis of the rectum is reported.
  • [MeSH-major] Adenocarcinoma / etiology. Endometrial Neoplasms / etiology. Endometriosis / complications. Rectal Diseases / complications. Sigmoid Diseases / complications

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078668.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 17
  •  go-up   go-down


46. van Niekerk CC, Bulten J, Vooijs GP, Verbeek AL: The Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the Endometrium. Obstet Gynecol Int; 2010;2010:465162
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the Endometrium.
  • Among 460 ovarian endometrioid carcinoma patients 53 cases showed a second primary endometrial cancer; 40 out of these 53 cases (75.5%) showed at both organ sites an endometrioid adenocarcinoma.
  • Conclusion. These findings suggest an important role for the endometrioid subtype and prompt to mechanism-based studies incorporating molecular techniques.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9344-50 [16361634.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):384-8 [17277759.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Nov;51(2):141-6 [8635635.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):456-62 [15297188.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(1):90-5 [14687794.001]
  • [Cites] Diagn Mol Pathol. 2003 Jun;12(2):71-8 [12766611.001]
  • [Cites] Cancer. 2003 May 15;97(10):2432-9 [12733142.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jan-Feb;13(1):32-7 [12631217.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):529-33 [11709271.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):355-62 [11606097.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2577-83 [9829719.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jan-Feb;18(1):159-64 [17506847.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):399-406 [18334710.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):783-9 [19305320.001]
  • (PMID = 20052276.001).
  • [ISSN] 1687-9597
  • [Journal-full-title] Obstetrics and gynecology international
  • [ISO-abbreviation] Obstet Gynecol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2796219
  •  go-up   go-down


47. Marchena-Gomez J, Conde-Martel A, Hemmersbach-Miller M, Alonso-Fernandez A: Metachronic malignant transformation of small bowel and rectal endometriosis in the same patient. World J Surg Oncol; 2006;4:93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metachronous progression of endometriosis to adenocarcinoma from two distant intestinal foci happening in the same patient has not been previously reported.
  • CASE PRESENTATION: We describe a case of metachronic transformation of ileal and rectal endometriosis into an adenocarcinoma occurring in a 45-year-old female without macroscopic pelvic involvement of her endometriosis.
  • Pathological examination revealed an ileal endometrioid adenocarcinoma and contiguous microscopic endometriotic foci.
  • An endoscopic biopsy revealed an adenocarcinoma.
  • A second endometrioid adenocarcinoma arising from a focus of endometriosis within the wall of the rectum was diagnosed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):890-2 [11391154.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1158-64 [9749501.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:2-10 [11093055.001]
  • [Cites] Ann Ital Chir. 2000 May-Jun;71(3):385-8 [11014020.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):18-22 [11006024.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):513-24 [10757398.001]
  • [Cites] Hum Pathol. 1998 May;29(5):491-7 [9596273.001]
  • [Cites] Acta Obstet Gynecol Scand. 1993 Nov;72(8):676-8 [8259757.001]
  • [Cites] Dis Colon Rectum. 1994 Aug;37(8):747-53 [8055717.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1163-9 [9740081.001]
  • [Cites] Obstet Gynecol. 1990 Jun;75(6):1023-8 [2188180.001]
  • [Cites] Obstet Gynecol. 1953 Sep;2(3):283-9 [13087921.001]
  • [Cites] Hum Reprod. 2004 Apr;19(4):996-1002 [15016784.001]
  • [Cites] Gynecol Oncol. 2001 Oct;83(1):100-8 [11585420.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1530-3 [11598486.001]
  • [Cites] Histopathology. 2002 Feb;40(2):171-6 [11952862.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):220-2 [12144831.001]
  • [Cites] Obstet Gynecol. 2002 Oct;100(4):788-95 [12383550.001]
  • [Cites] Int J Gynecol Pathol. 2001 Apr;20(2):133-9 [11293158.001]
  • (PMID = 17164003.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1712233
  •  go-up   go-down


48. Galgano MT, Conaway M, Spencer AM, Paschal BM, Frierson HF Jr: PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. Hum Pathol; 2009 Oct;40(10):1434-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All serous ovarian and endometrial endometrioid adenocarcinomas and mesotheliomas were immunoreactive for PRK1.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):40-6 [10728592.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):220-5 [18374401.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):908-11 [11221880.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):879-85 [11953818.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):990-1000 [12096084.001]
  • [Cites] EMBO J. 2003 Jan 15;22(2):270-80 [12514133.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] EMBO J. 2004 Aug 18;23(16):3303-13 [15282551.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):280-5 [7657393.001]
  • [Cites] JAMA. 1995 Dec 27;274(24):1926-30 [8568986.001]
  • [Cites] Obstet Gynecol. 1996 Oct;88(4 Pt 1):554-9 [8841217.001]
  • [Cites] Nat Biotechnol. 1997 Dec;15(13):1359-67 [9415887.001]
  • [Cites] Biochem J. 1998 Jun 1;332 ( Pt 2):281-92 [9601053.001]
  • [Cites] Nat Biotechnol. 1996 Dec;14(13):1675-80 [9634850.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):26-34 [15790433.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 [16341064.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):77-82 [16357568.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):779-85 [16721043.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5314-21 [17875760.001]
  • [Cites] Cancer Biol Ther. 2007 Jun;6(6):864-71 [17617741.001]
  • [Cites] Nat Cell Biol. 2008 Jan;10(1):53-60 [18066052.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • (PMID = 19427017.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104106-049003; United States / NCI NIH HHS / CA / P01 CA104106-04; United States / NCI NIH HHS / CA / P01 CA104106-049003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.1.- / protein kinase N; EC 2.7.11.13 / Protein Kinase C
  • [Other-IDs] NLM/ NIHMS98041; NLM/ PMC2744839
  •  go-up   go-down


49. Boyd C, Cameron I, McCluggage WG: Endometrial adenocarcinoma with signet ring cells: report of two cases of an extremely rare phenomenon. Int J Gynecol Pathol; 2010 Nov;29(6):579-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma with signet ring cells: report of two cases of an extremely rare phenomenon.
  • Signet ring cells are extremely rare in primary endometrial adenocarcinomas with only a single prior case report.
  • We report 2 cases of primary endometrial adenocarcinoma, one of mucinous and the other of endometrioid type, with a significant component of signet ring cells.
  • In reporting these cases, we illustrate that the presence of signet ring cells does not preclude a primary endometrial adenocarcinoma.We discuss signet ring cells in the endometrium.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881852.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Horn LC, Richter CE, Einenkel J, Tannapfel A, Liebert UG, Leo C: p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium. Ann Diagn Pathol; 2006 Aug;10(4):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathogenetically, endometrioid adenocarcinomas of the endometrium are associated with hyperestrogenism and serous papillary carcinomas with alterations of p53.


51. Cade TJ, Quinn MA, McNally OM, Neesham D, Pyman J, Dobrotwir A: Predictive value of magnetic resonance imaging in assessing myometrial invasion in endometrial cancer: is radiological staging sufficient for planning conservative treatment? Int J Gynecol Cancer; 2010 Oct;20(7):1166-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We compared MRI scans and final histopathologic diagnoses of 111 patients with endometrioid adenocarcinoma over a 6-year period at a major tertiary centre.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Magnetic Resonance Imaging. Myometrium / pathology. Patient Care Planning

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495220.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Ben-Arie A, Tamir S, Dubnik S, Gemer O, Ben Shushan A, Dgani R, Peer G, Barnett-Griness O, Lavie O: Does hysteroscopy affect prognosis in apparent early-stage endometrial cancer? Int J Gynecol Cancer; 2008 Jul-Aug;18(4):813-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of the study was to compare the outcome measures of patients with endometrial adenocarcinoma diagnosed by endometrial biopsy, uterine curettage, or hysteroscopy.
  • Medical records of 392 women diagnosed with apparent early-stage endometrial adenocarcinoma were reviewed.
  • There were 347 (88.5%) cases of endometrioid adenocarcinoma and 45 (11.5%) of poor histologic types, including serous papillary, clear cell, and small cell cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / surgery. Hysteroscopy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961159.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


53. Henson DE, Schwartz AM, Tilara A, Grimley PM, Anderson WF: Population-based analysis of pathologic data: a new approach to the investigation of uterine endometrial and ovarian endometrioid carcinomas. Arch Pathol Lab Med; 2007 Sep;131(9):1337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based analysis of pathologic data: a new approach to the investigation of uterine endometrial and ovarian endometrioid carcinomas.
  • CONTEXT: Population-based analysis of the histopathology of endometrioid adenocarcinoma of the endometrium and ovary combined with epidemiologic techniques offer a new approach to exploring the relationship of tumors that share a similar range of morphologic phenotypes.
  • Specifically, to test and compare whether the etiology/pathogenesis of ovarian endometrioid cancer is as dependent upon the reproductive environment as uterine endometrial carcinoma.
  • DESIGN: Graphic plots of the epidemiologic patterns were analyzed relating to incidence and age-specific rates of ovarian and uterine endometrioid carcinomas.
  • RESULTS: At all ages, uterine endometrioid carcinomas have higher incidence rates than their ovarian homologues.
  • In contrast, after age 50 (menopause), the incidence rates begin to diverge: the rates for uterine endometrial carcinomas continue to rise, whereas the rates for ovarian endometrioid carcinomas plateau.
  • Interestingly, endometrial stromal sarcomas follow an incidence rate pattern nearly identical to that of ovarian endometrioid carcinomas.
  • CONCLUSIONS: The continuum of cellular and molecular events predisposing to gynecologic cancers of endometrioid phenotype apparently cease to operate in the ovary after menopause, but additional cellular and molecular events appear to occur in the ageing uterine endometrium.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. SEER Program. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824787.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Giatromanolaki A, Koukourakis MI, Turley H, Sivridis E, Harris AL, Gatter KC, Tumour and Angiogenesis Research Group: Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. Mod Pathol; 2006 May;19(5):701-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Approximately, one-third of the 70 stage I endometrioid adenocarcinomas analysed exhibited an intense cytoplasmic and nuclear pKDR expression in both cancer cells and peritumoral vessels.
  • The unfavourable prognosis that VEGF confers to endometrial adenocarcinomas could be attributed to its angiogenic activity, but also to a direct effect on cancer cells through an autocrine VEGF/KDR loop.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16557278.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Phosphoproteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


55. Stewart CJ, Crook ML: Galectin-3 expression in uterine endometrioid adenocarcinoma: comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion. Int J Gynecol Pathol; 2010 Nov;29(6):555-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 expression in uterine endometrioid adenocarcinoma: comparison of staining in conventional tumor glands and in areas of MELF pattern myometrial invasion.
  • Endometrioid adenocarcinoma (EAC) of the uterus can show varying patterns of invasion, 1 of which, "MELF," is characterized by the presence of microcystic, elongated, and fragmented glands.
  • In this study, galectin-3 immunoreactivity was investigated in 22 EACs with specific comparison of staining in the "conventional" endometrioid-type tumor glands and in areas exhibiting MELF pattern invasion.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Galectin 3 / biosynthesis. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881856.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


56. Kato N, Toukairin M, Asanuma I, Motoyama T: Immunocytochemistry for hepatocyte nuclear factor-1beta (HNF-1beta): a marker for ovarian clear cell carcinoma. Diagn Cytopathol; 2007 Apr;35(4):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, two serous adenocarcinoma cell lines never showed immunoreactivity.
  • Based on these results, 21 archival Papanicolaou-stained slides of peritoneal fluid (5 CCCs, 12 serous, 2 mucinous, and 2 endometrioid adenocarcinomas) were decolorized and immunostained under heating pretreatment.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Biomarkers, Tumor / analysis. Hepatocyte Nuclear Factor 1-beta / metabolism. Immunohistochemistry / methods. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17351940.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alcohols; 0 / Biomarkers, Tumor; 0 / Fixatives; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


57. Pozharisskiĭ KM, Samsonova EA, Ten VP, Maksimova NA, Urmancheeva AF: [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value]. Arkh Patol; 2005 Mar-Apr;67(2):13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value].
  • 76 endometrioid adenocarcinomas of the uterine body were studied.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ki-67 Antigen / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Steroid / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938112.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Steroid; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


58. O'Gorman T, Olaitan A: Primary malignant melanoma arising in an ovarian cystic teratoma. Eur J Gynaecol Oncol; 2009;30(1):88-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology revealed a malignant melanoma and carcinoid tumour in the right ovarian teratoma and an endometrioid adenocarcinoma in the left ovary.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Dermoid Cyst / pathology. Melanoma / pathology. Neoplasms, Second Primary. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317266.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


59. Yahata T, Fujita K, Aoki Y, Tanaka K: Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod; 2006 Apr;21(4):1070-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term conservative therapy for endometrial adenocarcinoma in young women.
  • BACKGROUND: To evaluate the efficacy and safety of long-term conservative therapy with medroxyprogesterone acetate (MPA) for endometrial carcinoma in young patients who had experienced failure after initial therapy or relapse, we reviewed the clinical and pathologic records of eight patients diagnosed with well-differentiated endometrial adenocarcinoma without myometrial invasion who were treated with MPA for over 6 months because of treatment failure or relapse.
  • All presented well-differentiated endometrioid adenocarcinomas without extrauterine disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Medroxyprogesterone / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MEDROXYPROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16361282.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; HSU1C9YRES / Medroxyprogesterone
  •  go-up   go-down


60. Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG: Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol; 2007 Jul;26(3):328-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunohistochemical expression pattern of p16 in biopsy samples has been useful as part of a panel to distinguish adenocarcinomas arising from the endometrium from those arising from the endocervix.
  • Here, we retrospectively analyzed the immunohistochemical expression of p16 in 11 cases of USC (5 pure and 6 mixed with endometrioid adenocarcinoma) and 10 cases of ovarian high-grade serous carcinoma and compared p16 expression with that of p53 in the same samples. p16 was strongly expressed by 100% of tumor cells in all 11 uterine specimens and in 5 of the 10 ovarian specimens; of the other 5 ovarian specimens, 4 showed strong positivity in 20% to 80% of tumor cells, and 1 case showed only weak expression.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Papillomavirus Infections / metabolism. Tumor Suppressor Protein p53 / biosynthesis. Uterine Cervical Neoplasms / metabolism


61. Käufl SD, Makovitzky J, Kuhn C, Kunze S, Jeschke U, Mylonas I: Inhibin/activin-betaC subunit in human endometrial adenocarcinomas and HEC-1a adenocarcinoma cell line. In Vivo; 2010 Sep-Oct;24(5):695-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibin/activin-betaC subunit in human endometrial adenocarcinomas and HEC-1a adenocarcinoma cell line.
  • However, only limited data on the expression of the βC subunit in human endometrioid adenocarcinomas exist.
  • MATERIALS AND METHODS: Samples of uterine endometrioid adenocarcinomas were obtained and analysed by immunohistochemistry for the immunolabelling with an inhibin-βC antibody.
  • RESULTS: Expression of the inhibin-βC subunit was demonstrated at the protein level by means of immunohistochemical evaluation in human endometrioid adenocarcinomas and the HEC-1a cell line.
  • DISCUSSION: This study demonstrated, for the first time, that the novel inhibin/activin-βC subunit is expressed in human endometrioid adenocarcinomas and in the human endometrial carcinoma cell line HEC-1a.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Inhibin-beta Subunits / biosynthesis. Inhibin-beta Subunits / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20952735.001).
  • [ISSN] 1791-7549
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / INHBC protein, human; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


62. Dundr P: [Ovarian carcinoma: current diagnostic principles]. Cesk Patol; 2010 Jul;46(3):53-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Type I tumors include low-grade serous adenocarcinoma, low-grade endometrioid adenocarcinoma, mucinous adenocarcinoma, malignant Brenner tumor and some clear cell carcinomas.
  • Type II tumors are high-grade neoplasms including undifferentiated carcinoma, high-grade serous adenocarcinoma, high-grade endometrioid adenocarcinoma, malignant mixed Müllerian tumor and probably some clear cell carcinomas.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941958.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  •  go-up   go-down


63. Manini C, Montironi PL, Magistris A, Stramignoni D: Diagnostic value of micro-histology in endometrial brushing. Pathologica; 2010 Apr;102(2):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 13 of 15 malignant neoplasias (2 carcinosarcomas, 13 endometrioid adenocarcinomas) were correctly diagnosed in samples collected with Endoflower.

  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23596756.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


64. Nofech-Mozes S, Khalifa MM, Ismiil N, Dubé V, Saad RS, Sun P, Seth A, Ghorab Z: Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. Appl Immunohistochem Mol Morphol; 2010 Jan;18(1):80-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-risk human papilloma virus (HPV) seems to play a role in the pathogenesis of cervical squamous neoplasia and adenocarcinomas of the mucinous and endometrioid cell types.
  • Cervical serous, clear cell, and small cell carcinomas differ from the conventional endocervical adenocarcinoma in their clinical characteristics.
  • Our report documents HPV status in a series of archival unusual types of adenocarcinoma of the uterine cervix.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19625948.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Fixatives; 0 / Reagent Kits, Diagnostic; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


65. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP: The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol; 2006 Feb;30(2):230-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.
  • A proportion of adenocarcinomas in prophylactic adnexectomies (bilateral salpingo-oophorectomies [BSOs]) from women with BRCA mutations (BRCA positive) occur in the fallopian tube.
  • All tumors were Ki-67 positive (>75% of cell nuclei), and excluding one endometrioid carcinoma, p53 positive (>75% cell nuclei); p53 positivity in the absence of elevated Ki-67 did not correlate with morphologic neoplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Fallopian Tube Neoplasms / pathology. Genetic Predisposition to Disease. Ki-67 Antigen / metabolism. Ovarian Neoplasms / pathology


66. Gassler N, Yang SH, Keith M, Helmke BM, Schirmacher P, Obermüller N: Expression of acyl-CoA synthetase 5 in human endometrium and in endometrioid adenocarcinomas. Histopathology; 2005 Nov;47(5):501-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of acyl-CoA synthetase 5 in human endometrium and in endometrioid adenocarcinomas.
  • The aim of the present study was to characterize expression and localization of ACS5 in the normal human endometrium and in endometrioid adenocarcinomas.
  • Notably, in endometrioid adenocarcinomas, the ACS5 molecule was found abundantly in well-differentiated tumours, but not in poorly differentiated adenocarcinomas.
  • With regard to its value for histopathological diagnosis, immunohistochemical characterization of endometrioid adenocarcinomas shows that a decrease in ACS5 expression correlates with tumour dedifferentiation.
  • [MeSH-major] Carcinoma, Endometrioid / enzymology. Coenzyme A Ligases / biosynthesis. Endometrial Neoplasms / enzymology. Endometrium / enzymology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16241998.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 6.2.1.- / Coenzyme A Ligases; EC 6.2.1.- / acyl CoA synthetase 5
  •  go-up   go-down


67. Staats PN, Clement PB, Young RH: Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases. Am J Surg Pathol; 2007 Oct;31(10):1490-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases.
  • Vaginal adenocarcinoma is the second most common primary cancer of the vagina, yet there has been very little study of most subtypes other than clear cell carcinoma.
  • We reviewed 18 cases of primary vaginal endometrioid adenocarcinoma, in our experience the second most common subtype.
  • On microscopic examination, each of the tumors had a pure or predominant component of typical endometrioid adenocarcinoma.
  • Other subtypes of adenocarcinoma (such as serous when the tumor has a papillary pattern) and atypical forms of endometriosis, including polypoid endometriosis, are the most common other differential diagnostic considerations.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Cystadenocarcinoma, Serous / diagnosis. Diagnosis, Differential. Endometriosis / complications. Endometriosis / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895749.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Wu W, Lin Z, Zhuang Z, Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):50-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of mammalian microRNAs in endometrioid adenocarcinoma.
  • The specific expression profiles of miRNAs have been found in many human cancers, but there are few studies on endometrioid adenocarcinoma.
  • We found the miRNA expression profile in 10 pairs of endometrioid adenocarcinoma and adjacent nontumorous endometrium using human miRNA microarray.
  • Seventeen miRNAs exhibited higher expression and six miRNAs exhibited lower expression in endometrioid adenocarcinoma samples than those in the nontumorous samples in the microarray.
  • Of those, the miR-205, miR-449, and miR-429 were greatly enriched; in contrast the miR-204, miR-99b, and miR-193b were greatly downregulated in adenocarcinoma tissues.
  • This information may provide the candidate miRNA genome for further confirming the role of miRNAs in carcinogenesis of endometrioid adenocarcinoma and potentially serving as a diagnostic or therapeutic tool in endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometrial Neoplasms / genetics. Gene Expression Profiling. MicroRNAs / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077565.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


69. Jeong JW, Lee HS, Franco HL, Broaddus RR, Taketo MM, Tsai SY, Lydon JP, DeMayo FJ: beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus. Oncogene; 2009 Jan 08;28(1):31-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrioid adenocarcinoma is the most frequent form of endometrial cancer, usually developing in pre- and peri-menopausal women. beta-catenin abnormalities are common in endometrioid type endometrial carcinomas with squamous differentiation.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Feb 4;397(6718):405-9 [9989404.001]
  • [Cites] Endocrinology. 1999 Jan;140(1):484-91 [9886861.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1442-4 [10197610.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] Int Immunol. 1999 Mar;11(3):317-23 [10221643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] Mol Endocrinol. 1999 Jun;13(6):1005-17 [10379898.001]
  • [Cites] Mol Carcinog. 1999 Jul;25(3):207-18 [10411147.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3346-51 [10416591.001]
  • [Cites] J Reprod Fertil. 1964 Dec;8:331-8 [14248593.001]
  • [Cites] Mol Endocrinol. 2004 Dec;18(12):3035-49 [15358837.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1360-8 [15668893.001]
  • [Cites] Genesis. 2005 Feb;41(2):58-66 [15682389.001]
  • [Cites] Arch Histol Cytol. 2004 Dec;67(5):417-34 [15781983.001]
  • [Cites] Lab Invest. 2005 Jun;85(6):768-79 [15806138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8579-84 [15930138.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):605-19 [16021566.001]
  • [Cites] Dev Biol. 2005 Dec 1;288(1):276-83 [16256976.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):811-6 [16804722.001]
  • [Cites] FEBS Lett. 2006 Oct 16;580(24):5653-60 [17011554.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):269-73 [17224652.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):240-5 [17297296.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1175-86 [17159913.001]
  • [Cites] Dev Biol. 2007 Jul 15;307(2):227-36 [17532316.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(15):5468-78 [17515606.001]
  • [Cites] Trends Endocrinol Metab. 2007 Aug;18(6):234-9 [17588769.001]
  • [Cites] J Histochem Cytochem. 2007 Sep;55(9):963-74 [17533218.001]
  • [Cites] J Biol Chem. 2007 Oct 26;282(43):31725-32 [17711857.001]
  • [Cites] Annu Rev Pathol. 2007;2:57-85 [18039093.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):567-78 [10662781.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):323-6 [10671680.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):209-17 [11161379.001]
  • [Cites] J Pathol. 2001 Jan;193(1):95-101 [11169521.001]
  • [Cites] Development. 2001 Apr;128(8):1253-64 [11262227.001]
  • [Cites] J Pathol. 2001 May;194(1):59-67 [11329142.001]
  • [Cites] Oncogene. 2002 Nov 14;21(52):7981-90 [12439748.001]
  • [Cites] Yonsei Med J. 2002 Dec;43(6):701-11 [12497652.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):577-88 [14742263.001]
  • [Cites] Development. 2004 May;131(9):2061-72 [15073149.001]
  • [Cites] Mol Endocrinol. 2004 May;18(5):1238-50 [14976223.001]
  • [Cites] Biol Reprod. 2004 Aug;71(2):444-54 [15070830.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1260-5 [15492994.001]
  • [Cites] J Endocrinol. 1973 Jan;56(1):133-44 [4683406.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Mol Endocrinol. 1988 Dec;2(12):1243-8 [3216864.001]
  • [Cites] Endocrinology. 1989 Sep;125(3):1683-90 [2667965.001]
  • [Cites] J Biol Chem. 1989 Oct 5;264(28):16941-7 [2674144.001]
  • [Cites] Nature. 1992 Sep 3;359(6390):76-9 [1522892.001]
  • [Cites] Development. 1995 Nov;121(11):3529-37 [8582267.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):143-4 [9326929.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4736-8 [9354433.001]
  • [Cites] Development. 1998 Aug;125(16):3201-11 [9671592.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3526-8 [9721853.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Nature. 1998 Oct 15;395(6703):707-10 [9790192.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3005-10 [9865913.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):55-9 [10076565.001]
  • (PMID = 18806829.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01HD057873; United States / NICHD NIH HHS / HD / U54 HD007495-359009; United States / NICHD NIH HHS / HD / U54 HD007495-359022; United States / NCI NIH HHS / CA / R01 CA077530-09; United States / NICHD NIH HHS / HD / U54 HD007495-350006; United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CA / P50 CA098258-019001; United States / NICHD NIH HHS / HD / U54HD28934; United States / NICHD NIH HHS / HD / R03 HD077495; United States / NCI NIH HHS / CA / P50 CA098258; United States / NICHD NIH HHS / HD / U54 HD028934; United States / NICHD NIH HHS / HD / U54HD0077495; United States / NICHD NIH HHS / HD / R01 HD057873-01; United States / NICHD NIH HHS / HD / R01 HD042311-06A1; United States / NCI NIH HHS / CA / R01 CA077530; United States / NICHD NIH HHS / HD / U54 HD007495; United States / NICHD NIH HHS / HD / R01 HD042311; United States / NICHD NIH HHS / HD / R01HD042311; United States / NCI NIH HHS / CA / P50 CA083639-099005; United States / NCI NIH HHS / CA / R01-CA77530; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA098258-010003; United States / NICHD NIH HHS / HD / R01 HD057873
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, mouse; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS88308; NLM/ PMC2646831
  •  go-up   go-down


70. Kobayashi H: Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol; 2009 Oct;14(5):378-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although some endometriosis lesions may predispose to clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC) of the ovary, both of these cancers differ from the other histological types with respect to their clinical characteristics and carcinogenesis.
  • However, serous-type ovarian cancer may exhibit a rapid progression possibly through de-novo carcinogenesis.

  • Genetic Alliance. consumer health - Endometriosis.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2005 Jan-Feb;15(1):37-44 [15670295.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):309-17 [12648580.001]
  • [Cites] Lancet Oncol. 2009 Apr;10 (4):327-40 [19282241.001]
  • [Cites] J Obstet Gynaecol Res. 2008 Oct;34(5):872-7 [18834345.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):37-43 [17291229.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):466-70 [11104621.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] BMJ. 1993 Apr 17;306(6884):1030-4 [8490497.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):32-40 [18172249.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):342-6 [10053105.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):466-71 [12911723.001]
  • [Cites] BMJ. 1996 Nov 30;313(7069):1355-8 [8956699.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2086-91 [8635005.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:11-7 [11093056.001]
  • [Cites] Med J Aust. 2003 Jun 16;178(12 ):655-6 [12797860.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):676-82 [9919339.001]
  • [Cites] Curr Opin Obstet Gynecol. 2000 Feb;12 (1):39-42 [10752515.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):559-63 [10507786.001]
  • [Cites] Int J Gynaecol Obstet. 2001 Jul;74(1):45-50 [11430940.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):15-31 [14529658.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20 [17645503.001]
  • [Cites] Semin Reprod Med. 2003 May;21(2):209-22 [12917790.001]
  • [Cites] Fertil Steril. 2004 Aug;82(2):405-14 [15302291.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):268-71 [2893084.001]
  • [Cites] Am J Obstet Gynecol. 1997 Mar;176(3):572-9 [9077609.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10 ):1644-7 [10408412.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Apr;83(4):395-400 [15005789.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1612-8 [11920519.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:18-25 [11093057.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):255-64 [9633839.001]
  • [Cites] Int J Gynaecol Obstet. 2007 Nov;99(2):95-9 [17643440.001]
  • [Cites] Oncol Rep. 2009 Aug;22(2):233-40 [19578761.001]
  • [Cites] Int J Gynaecol Obstet. 1997 Dec;59(3):245-50 [9486515.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Apr;65(2):221-5 [8730628.001]
  • [Cites] Obstet Gynecol Clin North Am. 2001 Dec;28(4):637-51, vii [11766142.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):280-94 [12861175.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):315-25 [9633843.001]
  • [Cites] Clin J Oncol Nurs. 2003 Jan-Feb;7(1):41-7 [12629933.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jun;138(2):187-93 [18162283.001]
  • [Cites] Am J Epidemiol. 2002 Feb 1;155(3):217-24 [11821246.001]
  • (PMID = 19856043.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 41
  •  go-up   go-down


71. Flemming R, Sathiyathasan S, Jackson A: Endometrioid adenocarcinoma after insertion of a levonorgestrel-releasing intrauterine system. J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):771-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma after insertion of a levonorgestrel-releasing intrauterine system.
  • Endometrial biopsy specimen confirmed well-differentiated endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Contraceptive Agents, Female / therapeutic use. Endometrial Neoplasms / surgery. Intrauterine Devices / adverse effects. Levonorgestrel / therapeutic use. Menorrhagia / prevention & control

  • Hazardous Substances Data Bank. LEVONORGESTREL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971148.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 5W7SIA7YZW / Levonorgestrel
  •  go-up   go-down


72. Pijnenborg JM, Wijnakker M, Hagelstein J, Delvoux B, Groothuis PG: Hypoxia contributes to development of recurrent endometrial carcinoma. Int J Gynecol Cancer; 2007 Jul-Aug;17(4):897-904
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Effects of hypoxia on tumor protein p53 (TP53) expression were evaluated in the endometrial cancer cell lines (ECC-1), Ishikawa (derived from adenocarcinomas), and AN3CA (derived from a lymph node metastasis).
  • [MeSH-major] Carcinoma, Endometrioid / blood supply. Endometrial Neoplasms / blood supply. Endometrial Neoplasms / metabolism. Neoplasm Recurrence, Local / blood supply. Neoplasm Recurrence, Local / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17359291.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


73. Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M, Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol; 2008 Apr;109(1):122-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This study was conducted to determine whether tumor-associated macrophages (TAMs) correlate with clinicopathological features in endometrioid adenocarcinoma.
  • METHODS: 76 cases of endometrioid adenocarcinoma treated initially by hysterectomy with pelvic lymphadenectomy were retrospectively retrieved, and their histological features were evaluated.
  • TAMs may play a significant role in the biology of tumor progression of endometrial adenocarcinoma, but do not appear to be independent prognostic indicators of patient's survival.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Macrophages / pathology. Myometrium / pathology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289648.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


74. Matsuo T, Nakamura K, Takamoto N, Kodama J, Hongo A, Abrzua F, Nasu Y, Kumon H, Hiramatsu Y: Expression of the serine protease hepsin and clinical outcome of human endometrial cancer. Anticancer Res; 2008 Jan-Feb;28(1A):159-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Hepsin expression was examined by immunohistochemisty in 34 cases with normal endometrium as a control, 11 cases with endometrial hyperplasia, and 128 cases with endometrioid adenocarcinoma.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383840.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / hepsin
  •  go-up   go-down


75. Feng Y, Bommer GT, Zhai Y, Akyol A, Hinoi T, Winer I, Lin HV, Cadigan KM, Cho KR, Fearon ER: Drosophila split ends homologue SHARP functions as a positive regulator of Wnt/beta-catenin/T-cell factor signaling in neoplastic transformation. Cancer Res; 2007 Jan 15;67(2):482-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found that SHARP gene and protein expression is elevated in human colon and ovarian endometrioid adenocarcinomas and mouse colon adenomas and carcinomas carrying gene defects leading to beta-catenin dysregulation.

  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234755.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA082223; United States / NCI NIH HHS / CA / CA085463; United States / NCI NIH HHS / CA / CA094172
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Nuclear Proteins; 0 / SPEN protein, human; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


76. Wu TI, Chang TC, Hsueh S, Lai CH: Ovarian endometrioid carcinoma with diffuse pigmented peritoneal keratin granulomas: a case report and review of the literature. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):426-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian endometrioid carcinoma with diffuse pigmented peritoneal keratin granulomas: a case report and review of the literature.
  • The presence of keratin granulomas in peritoneal cavity associated with ovarian endometrioid carcinoma, which might be related to leakage from the ovarian tumor, is rarely reported.
  • The ovarian tumor was an endometrioid adenocarcinoma with squamous differentiation.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Granuloma / pathology. Lymph Nodes / pathology. Ovarian Neoplasms / pathology. Peritoneal Diseases / pathology


77. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM: HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol; 2006 May 20;24(15):2376-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The highest rate of HER-2 expression and amplification was seen in serous carcinoma (43% and 29%), while grade 1 endometrioid adenocarcinoma showed the lowest levels (3% and 1%).
  • For all histologic types, the rate of HER-2 expression and amplification was remarkably different (P < .0001) for grade 3 cancers (31% and 15%) versus grade 2 (7% and 3%) and grade 1 cancers (3% and 1%), with similar results for endometrioid type (P < .0001).

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Jul 20;24(21):3515. Maxwell, Larry G [corrected to Maxwell, G Larry]
  • (PMID = 16710036.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Zivanovic O, Carter J, Kauff ND, Barakat RR: A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol; 2009 Dec;115(3):504-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASES: Two young nulliparous women (29 and 23 years, respectively) with grade 1 endometrioid adenocarcinoma were initially treated with conservative fertility-sparing endocrine therapy.


79. Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, Shozu M, Isaka K: Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod; 2007 Jul;22(7):1953-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We planned a prospective study to conservatively treat women aged under 40 years with clinical stage 1A, grade 1 endometrioid adenocarcinoma from 1999 to 2005.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Progestins / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449880.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Progestins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


80. Hipp S, Walch A, Schuster T, Höfler H, Becker KF: Precise measurement of the E-cadherin repressor Snail in formalin-fixed endometrial carcinoma using protein lysate microarrays. Clin Exp Metastasis; 2008;25(6):679-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a first feasibility study, we examined 17 formalin-fixed endometrioid adenocarcinomas by protein lysate microarrays.

  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2003 Apr;3(4):317-25 [12726858.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5134-44 [16568079.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] J Pathol. 2007 Feb;211(3):370-8 [17133373.001]
  • [Cites] Gene. 2000 Oct 17;257(1):1-12 [11054563.001]
  • [Cites] Lancet. 2005 Aug 6-12;366(9484):491-505 [16084259.001]
  • [Cites] Oncogene. 2001 Apr 12;20(16):1981-9 [11360182.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] J Pathol. 2006 Apr;208(5):595-606 [16518808.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Oncogene. 2001 Mar 22;20(12):1525-8 [11313896.001]
  • [Cites] Virchows Arch. 2006 Mar;448(3):277-87 [16328348.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39209-16 [12161443.001]
  • [Cites] Gynecol Oncol. 1994 May;53(2):183-9 [8188077.001]
  • [Cites] Diagn Mol Pathol. 2007 Dec;16(4):222-8 [18043286.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • (PMID = 18307046.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Keratin-18; 0 / Snail Family Transcription Factors; 0 / Transcription Factors; 0 / Vimentin; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


81. Metindir J, Dilek GB: The role of omentectomy during the surgical staging in patients with clinical stage I endometrioid adenocarcinoma. J Cancer Res Clin Oncol; 2008 Oct;134(10):1067-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of omentectomy during the surgical staging in patients with clinical stage I endometrioid adenocarcinoma.
  • OBJECTIVE: The aim of this study was to evaluate whether omentectomy should be a routine part of staging surgery in endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Genital Neoplasms, Female / pathology. Genital Neoplasms, Female / surgery. Omentum / pathology. Omentum / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Gynecol Oncol. 1985 May;21(1):23-31 [3988126.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):34-8 [7821845.001]
  • [Cites] Int J Gynecol Cancer. 2003 Mar-Apr;13(2):212-5 [12657126.001]
  • [Cites] BJOG. 2002 May;109(5):576-8 [12066951.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):181-5 [12821361.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):471-4 [11906551.001]
  • [Cites] J Reprod Med. 1991 Sep;36(9):627-9 [1774722.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):795-8 [16681763.001]
  • [Cites] Oncology (Williston Park). 1990 Jun;4(6):21-6; discussion 30-2 [2144998.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jan-Feb;18(1):165-7 [17466052.001]
  • (PMID = 18386056.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


82. Bijen CB, Briët JM, de Bock GH, Arts HJ, Bergsma-Kadijk JA, Mourits MJ: Total laparoscopic hysterectomy versus abdominal hysterectomy in the treatment of patients with early stage endometrial cancer: a randomized multi center study. BMC Cancer; 2009;9:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INCLUSION CRITERIA: Patients with a clinical stage I endometrioid adenocarcinoma or complex atypical hyperplasia are randomized in a 2:1 allocation to receive TLH or TAH.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJOG. 2000 Nov;107(11):1386-91 [11117767.001]
  • [Cites] J Minim Invasive Gynecol. 2005 Mar-Apr;12(2):130-6 [15904616.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):239-44 [11161866.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):563-8 [11733973.001]
  • [Cites] J Am Assoc Gynecol Laparosc. 2002 Feb;9(1):54-62 [11821607.001]
  • [Cites] Int J Gynecol Cancer. 2002 Jan-Feb;12(1):57-61 [11860536.001]
  • [Cites] BMJ. 2004 Jan 17;328(7432):134 [14711748.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):789-93 [14984942.001]
  • [Cites] Health Technol Assess. 2004 Jun;8(26):1-154 [15215018.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jun;174(6):1795-9; discussion 1799-800 [8678142.001]
  • [Cites] Obstet Gynecol. 1998 Jan;91(1):30-4 [9464716.001]
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):270-5 [9988786.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):4-9 [15790430.001]
  • [Cites] Int J Gynecol Cancer. 2005 Mar-Apr;15(2):319-24 [15823119.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):378-87 [11180085.001]
  • (PMID = 19146684.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2630311
  •  go-up   go-down


83. Florio P, De Falco G, Leucci E, Torricelli M, Torres PB, Toti P, Dell'Anna A, Tiso E, Santopietro R, Leoncini L, Petraglia F: Urocortin expression is downregulated in human endometrial carcinoma. J Endocrinol; 2006 Jul;190(1):99-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we investigated whether UCN mRNA and peptide are expressed by human endometrial adenocarcinoma, and whether their expression changes compared to controls.
  • Samples of well (grade 1; n = 6 endometrioid adenocarcinoma, of whom n = 1 with squamous differentiation, and n = 1 clear-cell carcinoma) and poorly differentiated (grade 3; n = 3 endometrioid adenocarcinoma) endometrial adenocarcinoma were collected from nine women (age range 61-79 years) enrolled at the time of diagnosis.
  • UCN mRNA expression was significantly reduced (P < 0.0001) in endometrial adenocarcinoma than in healthy controls.
  • UCN mRNA and peptide expressions are decreased in endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Corticotropin-Releasing Hormone / metabolism. Down-Regulation. Endometrial Neoplasms / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837614.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Urocortins; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


84. Desrosiers L, Fadare O, Xiao ZF, Dresser K, Wang SA: Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium. Ann Diagn Pathol; 2008 Apr;12(2):112-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium.
  • This study was conducted to determine whether, in a pure population of patients with International Federation of Gynecology and Obstetrics stage I endometrioid endometrial (S1EE) carcinoma that is confined to the uterus and without lymph node metastases, the presence of lymphovascular space invasion (LVSI) is positively associated with vaginal relapses.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325471.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Li J, Kong WM: [Prognostic factors of stage III endometrial carcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Jan 20;89(3):198-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: The clinical data of 102 patients with stage III endometrial cancer, aged 54.9 (27-79), 71 with endometrioid adenocarcinoma, 31 with non-endometrioid adenocarcinoma, 9 undergoing simple surgical treatment, and 42 receiving radiation, 16 receiving chemotherapy, and 35 receiving chemoradiation after surgery, were analyzed retrospectively.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537039.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


86. Norimatsu Y, Yuminamochi T, Shigematsu Y, Yanoh K, Ikemoto R, Masuno H, Murakami M, Kobayashi TK: Endometrial glandular and stromal breakdown, part 3: cytomorphology of "condensed cluster of stromal cells". Diagn Cytopathol; 2009 Dec;37(12):891-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The material consists of 60 cases of cytologic smears for which histopathological diagnosis was obtained by endometrial curettage; they comprised 30 cases of EGBD and 30 cases of endometrioid adenocarcinoma grade 1 (G1).

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582808.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Ohishi Y, Kaku T, Oya M, Kobayashi H, Wake N, Tsuneyoshi M: CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls. Gynecol Oncol; 2007 Oct;107(1):30-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian tumors comprised 32 granulosa cell tumors, 3 Sertoli-stromal cell tumors, 14 fibrothecomas, 6 carcinoid tumors, 1 large cell neuroendocrine carcinoma, 17 endometrioid adenocarcinomas and 9 poorly differentiated serous adenocarcinomas.
  • RESULTS: All of the 32 granulosa cell tumors, all of the 3 Sertoli-stromal cell tumors, all of the 4 small cell carcinomas, 1 of 1 large cell neuroendocrine carcinoma, 11 of 14 fibrothecomas, 5 of 6 carcinoid tumors, 17 of 22 endometrial stromal sarcomas and 7 of 9 poorly differentiated serous adenocarcinomas were positive for CD56.
  • No immunoreactive cells were observed in 17 endometrioid adenocarcinomas or 47 ovarian follicles.
  • CD56 is useful in distinguishing between granulosa cell tumor and normal ovarian follicles or endometrioid adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583777.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
  •  go-up   go-down


88. Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL: Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer; 2009 Jul 1;115(13):2872-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy.
  • BACKGROUND: Ductal or endometrioid adenocarcinoma of the prostate may be a subtype of prostate cancer that is amenable to aggressive local therapeutic strategies.
  • The authors of this report investigated the clinical outcome of patients who had prostate ductal adenocarcinoma after primary radical prostatectomy or radiotherapy.
  • METHODS: The clinical features of 108 patients with locally confined or advanced prostate ductal adenocarcinoma who had undergone primary radical prostatectomy (surgical group, n = 76 men) or no surgery (nonsurgical group, n = 32 men) were evaluated retrospectively.
  • In addition, the median time to local progression was shorter (2.8 years vs 4.9 years) and the median time to distant metastasis was longer (3.9 years vs 2.0 years) for patients who had pure ductal adenocarcinoma than for patients who had mixed ductal adenocarcinoma of the prostate after surgery, respectively.
  • CONCLUSIONS: The results of this preliminary study suggested that pure ductal prostate adenocarcinoma tends to pursue an indolent clinical course and poses an increased risk for local recurrence.
  • Local control (particularly prostatectomy) may improve the clinical outcome of patients with pure prostate ductal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402048.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Logani S, Oliva E, Arnell PM, Amin MB, Young RH: Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol; 2005 Jan;18(1):19-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
  • Distinguishing primary ovarian carcinoma, particularly endometrioid and mucinous subtypes, from metastatic colorectal carcinoma to the ovary is often difficult on histologic examination alone.
  • We evaluated a panel consisting of antibodies to CDX2, beta-catenin and P504S in 23 primary ovarian adenocarcinomas (13 mucinous and 10 endometrioid) and compared the findings to 22 metastatic colorectal adenocarcinomas (seven mucinous and 15 nonmucinous tumors with endometrioid-like morphology hereafter referred to as pseudo-endometrioid) to the ovary stained with the same panel.
  • Strong (2+, 3+) and diffuse (>40%) expression for CDX2 was noted in 21 (95%) metastatic tumors and five (22%) primary ovarian tumors (three mucinous, two endometrioid).
  • Immunohistochemical expression of gene products and enzymes of colorectal carcinogenesis in some primary ovarian carcinomas suggest that the morphologic similarities between colorectal and mucinous/endometrioid carcinoma of the ovary extends to the genetic level, although differences in the level of expression exist between these tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers / analysis. Colonic Neoplasms / pathology. Colorectal Neoplasms / secondary. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15389251.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Homeodomain Proteins; 0 / Trans-Activators; 0 / beta Catenin; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


90. Giatromanolaki A, Sivridis E, Gatter KC, Turley H, Harris AL, Koukourakis MI, Tumour and Angiogenesis Research Group: Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecol Oncol; 2006 Dec;103(3):912-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Tissue specimens from 68 patients with clinical stage I endometrial adenocarcinoma of the endometrioid cell type and 20 samples from normally cycling endometrium were investigated immunohistochemically for the expression of LDH-5.
  • Endometrial adenocarcinomas displayed LDH-5 expression in 31/68 (45.5%) cases with those having a high LDH-5 expression being connected with a low lymphocytic response; this may suggest an important role of LDH-5 and, presumably, lactate release in tumor escape from host immuno-surveillance.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. L-Lactate Dehydrogenase / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • Genetic Alliance. consumer health - Endometrial cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837029.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Vascular Endothelial Growth Factor A; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.1.1.27.- / lactate dehydrogenase 5; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


91. Oaknin A, Barretina MP, Morilla I: Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: a case report. Eur J Gynaecol Oncol; 2010;31(1):114-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 69-year-old woman underwent surgery for FIGO Stage IA, grade 1 endometrioid adenocarcinoma of the endometrium.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Muscle Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349796.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


92. Posligua L, Malpica A, Liu J, Brown J, Deavers MT: Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread. Arch Pathol Lab Med; 2008 Nov;132(11):1821-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine carcinomas of the endometrium are rare tumors that can be pure, combined with endometrioid adenocarcinoma, or a component of malignant mixed müllerian tumor.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976022.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / R01 CA131183
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Erkanli S, Kayaselcuk F, Kuscu E, Bagis T, Bolat F, Haberal A, Demirhan B: Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer; 2006 May-Jun;16(3):1412-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to investigate if expressions of survivin and p27 proteins are involved in the development of endometrioid carcinoma, along with whether there are any correlations between these proteins and loss of wild-type PTEN that is found in up to 80% of endometrial carcinomas.
  • To our knowledge, this is the first time survivin expression is investigated in endometrial hyperplasia along with endometrioid adenocarcinoma.
  • For immunohistochemical analysis, 29 endometrioid adenocarcinoma, 38 endometrial hyperplasia, and 10 proliferative endometrium tissue samples were selected in the pathology archives.
  • None of these genes were correlated with classical prognostic factors such as grade and myometrial invasion in endometrioid adenocarcinoma.
  • Survivin overexpression might be one of the important mechanisms in the development of endometrioid adenocarcinoma along with lost or decreased activity of PTEN and p27.
  • However, survivin seems to exert its role in ways different from those of PTEN or p27 in the development of endometrioid adenocarcinoma.
  • These findings on the role of survivin in endometrioid adenocarcinoma should be confirmed and the pathways through which survivin acts in endometrioid adenocarcinoma studied further with a larger sample size.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. PTEN Phosphohydrolase / metabolism. Proliferating Cell Nuclear Antigen / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803539.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / p27 antigen; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


94. Lerwill MF, Young RH: Ovarian metastases of intestinal-type gastric carcinoma: A clinicopathologic study of 4 cases with contrasting features to those of the Krukenberg tumor. Am J Surg Pathol; 2006 Nov;30(11):1382-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian metastases of intestinal-type gastric adenocarcinomas are rare, and information on them is very limited compared with that on signet-ring cell carcinomas that result in the Krukenberg tumor.
  • Although information is limited, our results suggest that metastatic spread to the ovary by intestinal-type gastric adenocarcinoma is usually seen in patients older than those with Krukenberg tumors, with a known history of gastric carcinoma, and with concomitant widespread disease.
  • These metastatic intestinal-type tumors may be confused with metastases from other gastrointestinal sites that are more frequently the cause of pseudoendometrioid or mucinous metastases, and like such tumors may be confused with primary ovarian endometrioid and mucinous neoplasms.
  • [MeSH-major] Adenocarcinoma / secondary. Krukenberg Tumor / pathology. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology


95. Fujiwara H, Saga Y, Takahashi K, Ohwada M, Enomoto A, Konno R, Tanaka A, Suzuki M: Omental metastases in clinical stage I endometrioid adenocarcinoma. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):165-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omental metastases in clinical stage I endometrioid adenocarcinoma.
  • The clinical benefit of an omentectomy in endometrioid adenocarcinoma is unclear.
  • The objective of this study was to clarify the significance of an omentectomy performed for clinical stage I endometrioid adenocarcinoma.
  • A prospective study was performed on 134 patients with clinical stage I endometrioid adenocarcinoma who underwent omentectomy in addition to a staging laparotomy between 1998 and 2004: simple total hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymph node dissection, and peritoneal cytology.
  • The omental metastases rate for clinical stage I endometrioid adenocarcinoma was lower than the positive rates for extrauterine spread to other sites; thus, the routine application of omentectomy as a part of a staging laparotomy may not be efficacious.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Omentum / pathology. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466052.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Silva EG, Young RH: Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol; 2007 Aug;31(8):1203-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type.
  • In one such, those of endometrioid type, they are well known and generally readily characterized when they have the secretory pattern that recapitulates the well-known morphology of early secretory endometrium.
  • We reviewed 21 endometrioid tumors that occurred in patients from 27 to 88 (median 64) years.
  • One tumor was a cystadenofibroma, 1 a borderline tumor, and 19 were adenocarcinomas.
  • All the neoplasms had the typical architecture of endometrioid tumors but differed markedly in their cytoplasmic features.
  • Although a few cases had a focal slight resemblance to secretory endometrioid carcinoma most did not and the orderly morphology of classic secretory carcinoma was noteworthy for its absence.
  • The distinction from clear cell carcinoma depends on awareness of this unusual variant of endometrioid neoplasia and a lack of the distinctive patterns of clear cell carcinoma; at this time, special studies, including immunohistochemistry, do not aid significantly although certainly negative reactions, such as for thyroglobulin protein (arguing against clear cell struma ovarii) may play a role in some differential diagnostic considerations.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2007 Oct;31(10):1628
  • (PMID = 17667544.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


97. Mamat S, Ikeda J, Enomoto T, Ueda Y, Rahadiani N, Tian T, Wang Y, Qiu Y, Kimura T, Aozasa K, Morii E: Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma. Oncol Rep; 2010 May;23(5):1221-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma.
  • High level of CDCP1 expression proved to be a poor prognosticator for lung adenocarcinoma.
  • Here, expression level of CDCP1 was immunohistochemically examined in 110 cases (median age of 54.7 years) of endometrioid adenocarcinoma, and its clinical implications were evaluated.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Adhesion Molecules / analysis. Endometrial Neoplasms / chemistry. Neoplasm Proteins / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20372833.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDCP1 protein, human; 0 / Cell Adhesion Molecules; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


98. Chen YL, Hsiao SM, Lin MC, Lin HH: Bone metastasis as the initial presentation in one case of ovarian cancer with two components of endometrioid adenocarcinoma and adenosarcoma. Taiwan J Obstet Gynecol; 2009 Sep;48(3):298-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastasis as the initial presentation in one case of ovarian cancer with two components of endometrioid adenocarcinoma and adenosarcoma.
  • [MeSH-major] Adenosarcoma / secondary. Bone Neoplasms / secondary. Carcinoma, Endometrioid / secondary. Neoplasms, Second Primary / secondary. Ovarian Neoplasms / pathology


99. Heatley MK: Is female adnexal tumour of probable wolffian origin a benign lesion? A systematic review of the English literature. Pathology; 2009;41(7):645-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These lesions may be confused with well differentiated gynaecological cancers and careful clinicopathological correlation with the extensive use of immunohistochemistry is encouraged to ensure that lesions such as extragonadal endometrioid adenocarcinoma is not confused with FATWO.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001344.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 48
  •  go-up   go-down


100. Horrée N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP: Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol; 2007;29(3):219-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis.
  • METHODS: Expression of HIF-1alpha and proteins in the HIF-1alpha pathway (Glut-1, CAIX, VEGF) in paraffin-embedded specimens of normal (n=17), premalignant (n=17) and endometrioid endometrial carcinoma (n=39) was explored by immunohistochemistry, in relation to microvessel density (MVD).
  • CONCLUSION: HIF-1alpha and its downstream genes are increasingly expressed from normal through premalignant to endometrioid adenocarcinoma of the endometrium, paralleled by activation of its downstream genes and increased angiogenesis.
  • [MeSH-major] Carcinoma, Endometrioid / blood supply. Carcinoma, Endometrioid / metabolism. Neovascularization, Pathologic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452774.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Glucose Transporter Type 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  • [Other-IDs] NLM/ PMC4618415
  •  go-up   go-down






Advertisement